pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,425 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1156Endpoints875BioPharma Dive339BioSpace293Fierce Biotech277onclive165raps104globenewswire health73fda recalls
therapy area
allOncology7345Rare Disease1825Cardiology1672Immunology1455Hematology1302Vaccines1173Pulmonology1084Psychiatry & CNS
  • House passes stopgap bill to block White House plan for political control of federal research grants
    The House approved a temporary funding measure that blocks a White House proposal to let political appointees oversee federal research grants. The measure passed 370‑48 and mirrors a Senate bill p…
    STAT · 6d agoRegulatoryNeutral↗ source
  • NIH proposes cap on individual research grants, drawing mixed reactions
    The National Institutes of Health has floated a plan to limit the number of active research grants any single scientist can hold. The proposal is part of the agency’s effort to balance its research…
    STAT · 6d agoRegulatoryNeutral↗ source
← prev
page 3 of 57
next →
67
fda medwatch60
fda press38
858
Ophthalmology491
Pain468
Endocrinology & Metabolism465
Infectious Disease437
  • ADA internal review rejects claims of silencing protest after member expulsions
    An internal review by the American Diabetes Association examined the removal of five participants from its scientific sessions in New Orleans. The expulsions occurred after the individuals distribu…
    STAT · 5d agoNeutral↗ source
  • ADA reviews June conference disruptions, finds no censorship of editorial
    American Diabetes Association CEO Charles "Chuck" Henderson apologized after several attendees were removed from the June 5 Scientific Sessions in New Orleans for repeated disruptions. He said the…
    STAT · 5d agoNeutral↗ source
  • Trial over Lindsay Clancy’s case threatens progress in postpartum psychiatry
    Opinion piece by reproductive psychiatrist Jennifer Okwerekwu notes that the ongoing Lindsay Clancy trial, in which a jury remains deadlocked after five weeks, pits a defense claim of health-care s…
    STAT · 6d agoNegative↗ source
  • Dietitian Shortage Threatens Trump Administration's Nutrition Initiatives
    The Trump administration's Make America Healthy Again (MAHA) plan has shifted nutrition guidance, promoting more protein, cutting processed foods, and revamping meals in schools, military bases and…
    STAT · 6d agoNegative↗ source
  • FDA clears Protagonist-Takeda therapy for rare blood cancer as Lilly moves to buy Merida for up to $2.88 billion
    The U.S. Food and Drug Administration has granted approval to a collaborative therapy from Protagonist and Takeda aimed at treating a rare form of blood cancer. This regulatory decision adds a new…
    raps · 7d agoDealPositive↗ source
  • FDA approves Takeda/Protagonist cancer drug Mimrylo as White House readies new drug pricing deals, BioNTech ends colon vaccine trial
    The U.S. Food and Drug Administration gave approval to a weekly injection called Mimrylo, developed by Takeda and partner Protagonist Therapeutics, for treatment of a slow‑growing cancer. The agenc…
    STAT · 7d agoApprovalNeutral↗ source
  • New American Headache Society guidelines highlight expanded migraine prevention options
    The American Headache Society and the American Academy of Neurology released updated guidance on migraine prevention, the first revision since 2012. The new recommendations note that the FDA has a…
    STAT · 6d agoRegulatoryPositive↗ source
  • Trump announces nine new drug pricing agreements to align U.S. prices with peer nations
    President Trump announced a new round of voluntary pricing agreements with nine additional pharmaceutical companies, adding to the 17 firms that have previously signed similar deals. The companies…
    STAT · 6d agoDealPositive↗ source
  • Amgen faces FTC-backed lawsuit over patent-application purchase amid insurer dispute
    Amgen and a large health insurer are locked in a court fight over whether purchasing a drug patent application can be used to extend a monopoly on a medicine. The case is drawing attention because…
    STAT · 7d agoRegulatoryNegative↗ source
  • GLP-1 drugs push employers to rethink worker health-care costs
    GLP-1 medications are prompting many employers to reexamine how they fund employee health care. Rising prescription use and associated costs are forcing companies to consider new benefit designs an…
    STAT · 7d agoNegative↗ source
  • Personalized mRNA melanoma vaccine shows clinical success, reviving optimism for the platform
    Moderna and Merck reported positive results from a personalized mRNA vaccine designed to treat melanoma in a recent clinical study. The outcome is being hailed as a boost for mRNA technology, whic…
    STAT · 7d agoPositive readoutPositive↗ source
  • Experts urge FDA to boost transparency of complete response letters and refine master protocol guidance
    A recent paper in the Journal of Law and the Biosciences outlines ways the FDA could better disclose complete response letters to the public, aiming to increase transparency for stakeholders. Indu…
    raps · 7d agoRegulatoryNeutral↗ source
  • Radiopharmaceutical experts urge pharma to adopt bolder dosing despite safety concerns
    Louise Emmett and a group of radiopharmaceutical specialists argue that these modern radiation‑based drugs could dramatically improve cancer outcomes if used more aggressively. They say the therapi…
    STAT · 7d agoNeutral↗ source
  • Pregnancy hormone explored as possible guide for cardiovascular drug development
    The STAT+ newsletter preview highlights a discussion about whether a hormone that regulates pregnancy could be leveraged to direct a new cardiovascular therapy. The piece also notes that researche…
    STAT · 7d agoNeutral↗ source
  • Industry and patient groups urge FDA to revise master protocol guidance
    Industry groups and patient advocacy organizations have written to the U.S. Food and Drug Administration asking for several revisions to its recently updated draft guidance on master protocols for…
    raps · 7d agoRegulatoryNeutral↗ source
  • Highlights from the European Society of Cardiology meeting and updates on radiopharmaceutical research
    The newsletter reports that the European Society of Cardiology convened in Munich, with Europe correspondent Andrew Joseph providing coverage of the event. The author contrasts the ESC’s rotating…
    STAT · 7d agoNeutral↗ source
  • India streamlines regulations for outsourced medical device sterilization
    The Indian government announced a simplification of the regulatory framework governing outsourced sterilization of medical devices. The move is part of a broader effort to make it easier for busine…
    raps · 7d agoRegulatoryPositive↗ source
  • Study reports up to 25% of sampled NFL players had CTE at death, sparking calls for league-wide action
    Researchers in the Boston area examined the brains of a sample of former NFL players and found that about one quarter showed signs of chronic traumatic encephalopathy at death. The authors noted th…
    STAT · 7d agoNegative↗ source
  • FDA approves Mimrylo, a weekly injection for polycythemia vera, developed by Protagonist and sold by Takeda
    The Food and Drug Administration has approved a new therapy for polycythemia vera, a rare blood cancer that causes an overproduction of red blood cells. The drug, known as rusfertide, will be mark…
    STAT · 8d agoApprovalPositive↗ source
  • Alnylam defends its heart failure silencers after AstraZeneca's ATTR-CM trial miss
    AstraZeneca reported that its experimental drug Wainua failed to meet its primary endpoints in a study of transthyretin amyloid cardiomyopathy (ATTR-CM). The setback raised concerns about the thera…
    STAT · 8d agoNeutral↗ source
  • Novartis IL-6 antibody pacibekitug cuts inflammation markers in Phase 2 study
    A Phase 2 trial called TRANQUILITY showed that pacibekitug, an IL-6‑targeting antibody acquired by Novartis, reduced several biomarkers of inflammation in participants. The reductions were sustain…
    STAT · 9d agoPositive readoutPositive↗ source
  • AstraZeneca’s ATTR-CM Silencer Trial Fails to Show Benefit Over Existing Stabilizer Therapy
    AstraZeneca announced that its Phase 3 trial of a silencer drug for transthyretin amyloid cardiomyopathy (ATTR-CM) did not meet its primary endpoints. The study showed no additional clinical benefi…
    STAT · 10d agoNegative readoutNegative↗ source
  • Cytokinetics reports positive pivotal trial results for aficamten in non-obstructive hypertrophic cardiomyopathy
    Biotech Cytokinetics disclosed full data from a pivotal study of its drug aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The trial met both primary endpoints, showin…
    STAT · 10d agoPositive readoutPositive↗ source